Analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the stock.
Tonix Pharmaceuticals Trading Up 8.9 %
TNXP stock opened at $0.28 on Thursday. The company has a market capitalization of $52.09 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $12.48. The business has a 50 day simple moving average of $0.25 and a two-hundred day simple moving average of $0.33.
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Research analysts anticipate that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
- Five stocks we like better than Tonix Pharmaceuticals
- What is the MACD Indicator and How to Use it in Your Trading
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is the FTSE 100 index?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.